Provider review
Oria Meds Review: It Says "GLP-1" 107 Times and Never Names the Drug
We loaded every page of Oria's own site and counted. "GLP-1" appears 107 times. "Semaglutide" appears zero times, and so does "tirzepatide" — not in the visible text and not in the underlying markup either. You learn which molecule you are being sold at step two of the intake, after handing over your name, email, telephone number and shipping address.
Its NAD+ page is careful enough to claim nothing; its weight-loss pages say "GLP-1" 107 times without ever naming the molecule.
Worth trusting if
- You want a pharmacy named with a street address, which PerfectRx is
- You are reading the NAD+ page and value a seller that declines to promise an outcome
Be skeptical if
- You want to know which drug you are buying before handing over your contact and shipping details
- You are budgeting from the advertised figure, which matched nothing in the intake when we walked it
- You want to know which compounding rules govern your preparation, because the site never says
Compounded only
Phase 3 trials
Named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens oriameds.com. A link is not a recommendation to take anything.
Provenance
What Oria Meds actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- "Compounded GLP-1 medication" — the molecule is not named publicly — The card says from $149; when we walked the intake it offered $199 for one month and $209 for three or six — so committing longer costs more per month, and neither figure is the advertised one.
- NAD+ Support — No price is published for NAD+ on this page or anywhere else on the site.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
1
Molecules with human evidence
For the use they are sold for, out of 2 products reviewed here. The evidence belongs to the molecule, not to Oria Meds.
1
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Oria Meds’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
"Compounded GLP-1 medication" — the molecule is not named publiclySemaglutide · Compounded (503A)No trial supports this claim
“Doctor-led GLP-1 weight loss. You're not lazy. Your body isn't broken. Hunger hormones, cravings and a metabolism that fights back make weight loss genuinely harder. Oria is a GLP-1 clinic built around that reality, with licensed U.S. providers and medication delivered to your door. […] GLP-1 — Compounded GLP-1 medication — Starting at $149 /per month.”
Read on the Oria Meds site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4mg, 68 weeks. Cited here because the semaglutide the intake eventually offers is the molecule this trial tested — but the trial used the branded product, and no randomized trial of a compounded preparation has been published.
As of 2 September 2026, a census of Oria's own site — every route enumerated from the homepage and each page loaded, covering the eight distinct oriameds.com documents plus the portal and forms subdomains — found "semaglutide" 0 times and "tirzepatide" 0 times in visible text, and 0 times in the underlying page text as well. "GLP-1" appeared 107 times in visible text across the same pages. The molecule is disclosed at step 2 of the intake, after name, email, telephone number and shipping address.
There is no claim here to check against evidence, because there is no drug here to check evidence for. "Compounded GLP-1 medication" is a class and a dosage form; semaglutide and tirzepatide have different trials, different effect sizes, different side-effect profiles and, on this site, different prices — and a reader cannot tell which one is being offered until they have given up four pieces of personal information. The emotional copy above it does real work in the meantime: "You're not lazy. Your body isn't broken" is a sympathetic and accurate thing to say about weight regulation, and it arrives where a product name should be.1
NAD+ SupportNAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)Claim matches the trials
“NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in cellular energy metabolism. NAD+ support may be clinically reviewed for appropriate patients seeking precision wellness care. […] It plays a central role in cellular energy metabolism and is involved in various biological processes. This is not a treatment for any disease, and no specific outcomes are guaranteed. […] These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”
Read on the Oria Meds site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search for injected NAD+ in humans returns no completed randomized trial supporting a restoration-of-function claim, and a PubMed search for nicotinamide adenine dinucleotide combined with injection or subcutaneous, filtered to the randomized-controlled-trial publication type, returns zero records. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
Nothing here overreaches, because nothing here reaches. Every sentence on this page describes either textbook biochemistry — NAD+ is a coenzyme in cellular energy metabolism, which is true — or a review process, as in "may be clinically reviewed for appropriate patients". No outcome is promised, and the page states plainly that this is not a treatment for any disease and that no specific outcomes are guaranteed. On a molecule with no completed randomized trial by this route, declining to claim anything is the only defensible position, and Oria takes it. The cost is that a prospective buyer finishes the page knowing what NAD+ is in a cell and nothing whatever about why they should buy it — and no price is published for it anywhere.2
Dispensing chain
Who actually fills your prescription
- PerfectRx
Read the full account
Oria names its pharmacy — PerfectRx, at 5810 Long Prairie Rd, Flower Mound, Texas — which is more than most of this market discloses, and the NAD+ page names it in the fulfillment step rather than burying it in the terms. Two things are missing around that. No compounding category is published: we counted, and "503A" appears zero times in the visible text of any page, surviving only inside unrendered script, while "503B" appears nowhere at all. Markup a reader never sees is not disclosure, so the accurate statement is that the site does not say which rules govern the preparation. And no legal entity is published anywhere — the Terms name only the brand, describing "Oria Meds" as "a technology platform that facilitates" the service, with no corporation, no limited liability company and no registered address. No individual clinician is named either.
Read on the Oria Meds site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency, purity or sterility result is published. The NAD+ page carries the disclosure language most of this market omits — that the statements have not been evaluated by the Food and Drug Administration, that the product is not intended to diagnose, treat, cure or prevent any disease, and that no specific outcomes are guaranteed. That care sits oddly beside the weight-loss side of the same site, which never names the drug it sells at all.
Read on the Oria Meds site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
The homepage badge row says "Licensed providers in all 50 states". No per-state list is published, and the NAD+ page adds that eligibility includes "patients residing in a state where telehealth services are available", without saying which states those are.
Read the full licensing claim
No clinician is named — no prescriber, no medical director, no advisory panel — and no legal entity is published. The Terms describe "Oria Meds" only as a technology platform. The named pharmacy partner is PerfectRx of Flower Mound, Texas.
Read on the Oria Meds site, September 2026.
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- It names its pharmacy, PerfectRx, with a street address, and names it in the fulfillment step rather than only in the terms.
- Its NAD+ page makes no efficacy claim at all — on a molecule with no completed randomized trial by this route, that is the only defensible position.
- That page states plainly that this is not a treatment for any disease and that no specific outcomes are guaranteed.
Show 3 more
- It carries the not-evaluated-by-FDA and not-intended-to-diagnose language that much of this market omits.
- Its weight-loss copy is sympathetic and accurate about why weight regulation is hard, rather than blaming the reader.
- No FDA warning letter against Oria Meds or PerfectRx.
- Neither semaglutide nor tirzepatide is named anywhere on their site — we counted every page, in visible text and in the underlying markup.
- "GLP-1" appears 107 times in its place, which is a drug class, not a drug.
- The molecule is disclosed at step two of the intake, after name, email, telephone number and shipping address.
Show 7 more
- The two molecules have different trials, different effect sizes and different prices here, and a reader cannot tell which is on offer.
- No compounding category is published — "503A" survives only in unrendered script, which a reader never sees, and "503B" appears nowhere.
- No legal entity is published; the Terms name only the brand and call it a technology platform.
- The advertised starting prices matched no figure in the intake menu when we walked it.
- The semaglutide ladder is inverted — committing to three or six months costs more per month than one.
- No price is published for NAD+ anywhere on the site.
- No clinician is named.
Verdict
The bottom line
Find out which molecule you are being prescribed before you give this site your address. The public pages say "GLP-1" over a hundred times and name neither semaglutide nor tirzepatide once, and those are different drugs with different trials, different effect sizes and, here, different prices. The NAD+ page is the opposite problem and much the smaller one: it is so careful that it promises nothing at all, which is the right posture for that molecule and leaves a buyer with no reason to want it.
Opens oriameds.com. A link is not a recommendation to take anything.
We counted
Oria's own site enumerates to eight distinct pages on its own domain, plus a portal and a forms subdomain. We loaded every one and counted the drug names — in the visible text, and again in the full underlying page text in case something was hidden:
| Term | Visible | In the page text | |---|---|---| | GLP-1 | 107 | 212 | | semaglutide | 0 | 0 | | tirzepatide | 0 | 0 |
The treatment card, verbatim:
GLP-1 · Compounded GLP-1 medication · Starting at $149 /per month
"GLP-1" is a class of drug, the way "antibiotic" is. Semaglutide and tirzepatide are different molecules with different trials, different effect sizes, different side-effect profiles and — on this very site — different prices.
You find out which one you are being offered at step two of the intake, after your name, email address, telephone number and shipping address.
Full analysis — 4 more sectionsWhat sits where the drug name should be · The compounding category is not published · The NAD+ page has the opposite problem · The prices that were not there
What sits where the drug name should be
"Doctor-led GLP-1 weight loss. You're not lazy. Your body isn't broken. Hunger hormones, cravings and a metabolism that fights back make weight loss genuinely harder."
That is a sympathetic paragraph and it is broadly accurate about weight regulation — this is not a case of a seller telling a lie. It is a case of a seller filling the space where a product name belongs with a paragraph about how the reader feels.
The compounding category is not published
We counted this too. "503A" appears zero times in the visible text of any page. It survives only inside unrendered script — markup a reader never sees. "503B" appears nowhere at all.
Text in the source that never renders is not disclosure. The accurate statement is that Oria does not tell you which set of rules governs the preparation you would receive.
Similarly, no legal entity is published. The Terms name only the brand, describing "Oria Meds" as "a technology platform that facilitates" the service — no corporation, no limited liability company, no registered address.
What is named, and creditably, is the pharmacy: PerfectRx, at a street address in Flower Mound, Texas, identified in the fulfillment step rather than buried in the terms.
The NAD+ page has the opposite problem
Read it closely and it claims nothing:
"NAD+ … is a coenzyme involved in cellular energy metabolism."
"NAD+ support may be clinically reviewed for appropriate patients seeking precision wellness care."
"This is not a treatment for any disease, and no specific outcomes are guaranteed."
Every sentence is either textbook biochemistry or a description of a review process. No outcome is promised anywhere. It adds that the statements have not been evaluated by FDA and that the product is not intended to diagnose, treat, cure or prevent any disease.
For a molecule with no completed randomized trial by this route 2, declining to claim anything is the only defensible position available, and Oria takes it. Credit where it is due.
The cost is that you finish the page knowing what NAD+ does inside a cell and nothing about why you should buy it. No price is published for it either.
The prices that were not there
The homepage advertises from $149 and $249.
When we walked the intake on 1 September 2026, the menu offered $199, $209 and $209 for semaglutide, and $369, $316 and $299 for tirzepatide. Neither advertised figure appears in that menu.
And the semaglutide ladder runs backwards: one month at $199 per month, three and six months at $209 per month. Committing longer costs more.
Questions
Frequently asked questions
Which drug does Oria actually sell?
Their site never says. We loaded every page and counted: "semaglutide" appears zero times and "tirzepatide" zero times, in visible text and in the underlying markup alike, while "GLP-1" appears 107 times. Both molecules are offered at step two of the intake, after you provide your name, email, telephone number and shipping address.
Does it matter which one it is?
Yes. Semaglutide and tirzepatide were tested in different trials with different reported effect sizes and different side-effect profiles, and on this site they carry different prices. "GLP-1" names the class, not the drug — it is about as specific as "antibiotic".
Is the NAD+ claim supported?
There is no claim to support, which is the fair answer. The page describes NAD+ as a coenzyme involved in cellular energy metabolism — true biochemistry — says the treatment may be clinically reviewed for appropriate patients, and states outright that it is not a treatment for any disease and that no specific outcomes are guaranteed. Since no completed randomized trial of NAD+ by this route exists, claiming nothing is the only defensible position.
Does Oria use a 503A or a 503B pharmacy?
The site does not say. We counted: "503A" appears zero times in the visible text of any page and survives only inside script a reader never sees, and "503B" appears nowhere at all. It does name the pharmacy itself — PerfectRx, in Flower Mound, Texas — which is more than most sellers here disclose.
What will I pay?
Not the advertised figure, on the evidence of our walk. The homepage advertises from $149 and $249; the intake menu offered $199, $209 and $209 for semaglutide and $369, $316 and $299 for tirzepatide, and neither advertised number appeared in it. Note also that the semaglutide ladder is inverted — three and six months cost more per month than one.
Who runs Oria Meds?
The site does not say. No legal entity is published anywhere; the Terms name only the brand and describe it as a technology platform. No clinician, medical director or advisory name appears either.
Glossary
Key terms
Show definitions
- GLP-1
- A class of drug, not a single medicine. Semaglutide and tirzepatide are both described this way and are different molecules with separate trials, effect sizes and safety profiles — tirzepatide additionally acts on a second receptor.
- Rendered versus source text
- What a page displays, against what sits in its underlying code. A statement that exists only in the source and never appears on screen has not been disclosed to the reader, whatever a search of the file would suggest.
Compare
Others selling what Oria Meds sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Oria Meds's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 participants, 68 weeks, mean weight reduction 14.9%; the trial used branded semaglutide and no randomized trial of a compounded preparation has been published. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- US National Library of Medicine (2026). PubMed search: nicotinamide adenine dinucleotide AND (injection OR subcutaneous) AND randomized controlled trial[pt] — zero records for injected NAD+ in humans. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=nicotinamide+adenine+dinucleotide+AND+injection+AND+randomized+controlled+trial%5Bpt%5D
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.